公开(公告)号：US20180231557A1

公开(公告)日：2018-08-16

申请号：US15952731

申请日：2018-04-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Friedemann Krause ,  Vinzent Rolny ,  Farshid Dayyani ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Julia Riedlinger ,  Felix Herth ,  Thomas Muley

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N33/57484 ,  G01N2333/4742 ,  G01N2333/70596

Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.

公开(公告)号：US20230305010A1

公开(公告)日：2023-09-28

申请号：US18309985

申请日：2023-05-01

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Anika Mang ,  David Morgenstern ,  Vinzent Rolny ,  Magdalena Swiatek-De Lange

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  G01N2333/8146 ,  G01N2333/96494 ,  G01N2470/04 ,  G01N2800/50 ,  G01N2800/08

Abstract: The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.

公开(公告)号：US20180292410A1

公开(公告)日：2018-10-11

申请号：US16008550

申请日：2018-06-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Friedemann Krause ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Vinzent Rolny ,  Sandra Rutz ,  Thomas Muley ,  Felix Herth ,  Julia Riedlinger

IPC: G01N33/574

Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.